Pharmaceutical Technology

APRIL 4, 2023

Formerly known as CTX001, exa-cel is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy. We want to thank the clinical trial participants and the sickle cell and beta thalassemia communities, as well as the physicians, nurses, coordinators, caregivers and friends who support them.”

Gene Therapy 246

Gene Therapy Gene Editing In-Vivo Gene 246

The Pharma Data

NOVEMBER 16, 2020

The gene edit prevents the virus from performing its normal evasive maneuver: hiding out in nervous system cells in order to elude the immune system. MONDAY, Nov. 16, 2020 — Scientists are reporting early success with an experimental herpes vaccine that uses a genetically modified version of the virus.

Vaccine 52

Vaccine Vaccination Immune Response Genetics 52

XTalks

FEBRUARY 10, 2023

Medpace has IP experience with both autologous and allogeneic cellular products, ex vivo and in vivo gene transfer, and a number of different gene-editing mechanisms. An overview of Medpace’s experience in conducting cell and gene therapy trials. If so, why?

Clinical Trials 52

Clinical Trials Clinical Trials Trials Gene Therapy 52

The Pharma Data

JANUARY 24, 2021

National Institute of Allergy and Infectious Diseases (NIAID), of bamlanivimab (LY-CoV555) decreased the risk of COVID-19 among residents and staff of long-term care facilities, i.e., nursing homes. CYAD-101 is the company’s allogeneic NKG2D-receptor and T cell receptor inhibitory molecule-based, non-gene edited CAR-T candidate.

Trials 52

Trials Allergies In-Vitro Antibody 52

Pharmaceutical Technology

FEBRUARY 23, 2023

It covers a broad range of techniques from the less invasive practice of intermittent fasting to drastic and invasive procedures, such as the implanting of microchips or injecting of gene-editing enzymes. nurses, doctors, and hospital auxiliary staff) to meet these needs.

Gene Editing 278

Gene Editing Regulation Production Nurses 278